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Abstract
Introduction: Late relapse of a testicular germ cell tumour is an uncommon occurrence. We
report a case of osteolytic bone metastasis appearing 23 years after the initial treatment of
a metastatic testicular mixed tumour (choriocarcinoma and embryonal carcinoma). This is one of the
longest periods of recurrence reported for testicular germ cell tumours.
Case presentation: A 52-year-old Caucasian man who underwent a right inguinal orchiectomy due
to testicular tumour in 1984 presented to our outpatient clinic in a generally bad condition of health
and with severe pain of his right hip joint and os ischii caused by osteolytic metastasis.
Conclusions: This case emphasizes the need for a life-long follow-up of patients with primary
metastatic testicular cancer.
Introduction
The prognosis of malignant testicular tumour has drama-
tically improved due to cisplatin-based chemotherapy.
When diagnosed at an early stage, the disease has a cure
rate of 95% to 100%. In advanced stages, cure rates of up
to 70% are still possible [1]. However, after surgical
therapy and cisplatin containing chemotherapy, up to
10% of patients monitored have developed relapses
despite being pronounced tumour-free. The majority of
these relapses developed during the first two years [2].
However, in a small number of patients, late relapses
were noted [2].
The most complete report of late relapse was published by
Baniel et al. [3]. The authors demonstrated that germ cell
tumours in a situation of late relapse exhibit a biological
behaviour that is different from the primary tumours. An
early relapse incidence of 2% to 3% was calculated. The
median time of appearance for late relapse was six years,
and the main localisation was the retroperitoneum and
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marker alpha-fetoprotein (AFP). Late relapse was sensitive
to chemotherapy, although chemotherapy alone is
normally insufficient to achieve a complete cure. The
most efficacious therapy was surgical resection of the
tumour mass.
We report here a case of a late relapse of a germ cell
tumour, which occurred 23 years after orchiectomy and
following four cycles of chemotherapy and five years of
complete remission.
Case presentation
A 52-year-old man presented to our outpatient clinic in
a bad general condition of health and with severe pain of
his right hip joint and os oschii. The pain developed
approximately three months prior to presentation.
The patient’s medical history revealed a right inguinal
orchiectomy for the removal of testicular tumour per-
formed in France in 1984. The rest of his anamnesis was
clinically insignificant.
In 1984, the patient’s histopathology revealed a mixed
tumour, a choriocarcinoma and an embryonic carcinoma,
with retroperitoneal and pulmonary metastases. To treat
this, an orchiectomy was performed, followed by four
cycles of bleomycin, etoposide and cisplatin (BEP)
chemotherapy. Follow-up assessments were initially per-
formed at an interval of three months, and then at an
interval of six months until the fifth postoperative year.
Whenthepatientpresentedto ourclinic,heappearedtobe
inbadgeneralhealth,withseverepaininhisrighthipjoint.
His serum level of alpha-fetoprotein was 169.48 ng/ml
(normalrange0.0to7.0ng/ml)andbeta-humanchorionic
gonadotropin (ß-hCG) was 1.30 mIU/ml (normal range
<5.0 mIU/ml). The patient’s lactate dehydrogenase (LDH)
level was 1155 U/L (normal range 230 to 460 U/L) and his
alkaline phosphatase level was 104 U/L (normal range is
3 to 128 U/L).
Radiological investigation, which was later confirmed
through computer tomograms, demonstrated that there
was an osteolytic destruction of the patient’s os ischii and
hip joint (Figure 1). In addition, enlarged lymphatic nodes
were found on the patient’s retroperitoneal space. Two
pulmonary metastases were also found in his left lung
(Figure 2).
A biopsy of the lytic bone lesion was carried out to confirm
the diagnosis. Histological and immunohistochemical
investigation of the biopsy cylinders showed an anaplastic
seminoma (Figure 3). Immunohistochemical testing was
positive for alpha-fetoprotein but negative for hCG,
carcinoembryonic antigen (CEA), CD30 and CD117
(C kit).
Due to strong pain, analgesia with peripheral and central
analgesics was initiated. During the next three days,
however, the state of our patient dramatically declined
and he died a day before the results of the biopsy were
known.
Discussion
After initial therapy, patients with germ cell tumours who
have two years of complete remission have a high cure
rate. The probability of a late relapse is between 1.3% and
7% [4-6]. Late relapses of nonseminomatous tumours are
more frequent [4].
Late relapse is defined as a germ cell tumour that appears
more than two years after therapy and complete remission
[3]. Of the 81 patients treated at the University of Indiana
for late relapse of germ cell tumours, 60% showed late
relapse more than five years after primary therapy and
complete remission [3].
A series of 1263 patients with germ cell testicular tumour
treated at the Department of Radiotherapy and Oncology
in Surrey, United Kingdom showed that only 14 patients
had late relapse between the 5th and 10th year after
primary treatment with a calculated annual risk of 1%. In
two patients, late relapse occurred later than 10 years. One
of these patients presented with metastatic seminoma,
while the other presented with nonseminoma during
the clinical stage I, which was then followed up by a wait-
and-see attitude [7].
Figure 1. Osteolytic destruction of the patient’s right os
ischii.
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relapses are identified as: 1) the presence of mature
teratoma in the germ cell tumour; 2) the growth of the
remaining tumour not destroyed by the chemotherapy;
and 3) the development of a secondary germ cell
carcinoma and the microscopic persistence of tumour
cells with atypical biological behaviour [8].
Albers et al. wrote the European Association of Urology
(EAU) guidelines on testicular cancer in a limited update
in March 2009. Precise recommendations for minimum
follow-up schedules in advanced nonseminomatous germ
cell tumours and seminoma were provided, indicating the
procedures that should be performed at one, two and three
to five years after initial therapy and thereafter [9].
Late relapses respond weakly to chemotherapy. Surgical
excision remains the best treatment. Baniel et al. showed
that chemotherapy alone yields poor results in patients
with late relapse [3]. Tumour-free status was achieved by
chemotherapy in only two out of 81 patients. In patients
who did not initially receive chemotherapy to treat the
germ cell tumour, complete remission could be reached
during late relapse by chemotherapy alone [3].
Conclusions
Late relapse of malignant germ cell tumours are a rare
occurrence. Until recently, it was generally considered
sufficient to perform follow-up assessments for up to five
years after initial therapy. However, metastatic nonsemi-
nomatous tumours form an exception to this general rule,
and late tumour relapses do occur. It thus seems necessary
that follow-up examinations be performed for longer than
five years after the primary therapy. This regime is
recommended in the latest 2009 update of the EAU
guidelines on testicular cancer as written by Albers and his
co-authors.
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